1. Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma

   • Anne-Gaëlle Dosne
   • Elodie Valade
   • Juan Jose Perez Ruixo

   Original Article Open access 03 January 2022 Pages: 151 - 164

   

2. Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies

   • Elmira Karami
   • Shamsi Naderi
   • Fatemeh Kazemi-Lomedasht

   Original Article 06 January 2022 Pages: 165 - 172

   

3. Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis

   • Mingrui Yan
   • Xiaoyu Fan
   • Yong Liu

   Original Article 06 January 2022 Pages: 173 - 181

   

4. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway

   • Peng Xu
   • Handong Wang
   • Chulei Deng

   Original Article Open access 08 January 2022 Pages: 183 - 196

   

5. Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach

   • Manon Reda
   • Pauline Macaire
   • Antonin Schmitt

   Original Article 08 January 2022 Pages: 197 - 208

   

6. Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma

   • Xi-zhi Wen
   • Qiu-zhong Pan
   • Xing Zhang

   Original Article 13 January 2022 Pages: 209 - 215

   

7. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2

   • Lei Chen
   • Zhangke Li
   • Shiwen Guo

   Original Article 17 January 2022 Pages: 217 - 229

   

8. Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice

   • Brian F. Kiesel
   • Jianxia Guo
   • Jan H. Beumer

   Original Article 23 January 2022 Pages: 231 - 242

   

9. Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota

   • Junmin Liu
   • Wei Luo
   • Hongbo Sun

   Original Article Open access 23 January 2022 Pages: 243 - 253

   

10. Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma

    • Ryan H. Moy
    • Megan Greally
    • Geoffrey Y. Ku

    Clinical Trial Report 23 January 2022 Pages: 255 - 265

    

11. Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement

    • Annalisa Condorelli
    • Cristina Matteo
    • Francesco Di Raimondo

    Short Communication 29 September 2021 Pages: 267 - 270

12. Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites

    • Stefanie D. Krens
    • Sasja F. Mulder
    • Nielka P. van Erp

    Short Communication 01 December 2021 Pages: 271 - 274

    

13. Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment

    • Kate R. Secombe
    • Elise E. Crame
    • Joanne M. Bowen

    Short Communication 02 December 2021 Pages: 275 - 281

    

14. Correction to: Anticancer potential of metformin: focusing on gastrointestinal cancers

    • Mohammad rafi Khezri
    • Hassan Malekinejad
    • Morteza Ghasemnejad-Berenji

    Correction 02 August 2021 Pages: 283 - 283